Results 171 to 180 of about 251,190 (359)

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma [PDF]

, 2020
Olfat Kamel Hasan, Aravind S. Ravi Kumar, Grace Kong, Kira Oleinikov, Simona Ben‐Haim, Simona Grozinsky‐Glasberg, Rodney J. Hicks   +6 more
openalex   +1 more source

Prospects of functionalized porous materials towards extraction of spent nuclear fuel radionuclides [PDF]

, 2021
Adede Simon Ochieng, Meng Zhang, Yaori Li, Anselim M. Mwaura   +3 more
openalex   +1 more source

Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next‐Generation Diagnostics and Biosensing

Advanced Science, Volume 13, Issue 2, 9 January 2026.
The advent of aptamers has highlighted their potential as alternatives to antibodies, overcoming limitations of structural instability and production cost. However, conventional approaches such as SELEX remain slow and labor‐intensive. This review examines recent advances in aptamer engineering, emphasizing in vitro and AI‐driven in silico strategies ...
John V. L. Nguyen, Ahlem Meziadi, Cyrill Brunner, Maureen McKeague, Lidija Malic, Maryam Tabrizian   +5 more
wiley   +1 more source

MXene‐Enhanced Electromembrane Systems for Advanced Water Applications: A Review

Advanced Energy and Sustainability Research, Volume 7, Issue 1, January 2026.
MXenes, synthesized via etching, intercalation, and delamination, exhibit hydrophilicity, conductivity, tunability, and strength, enabling roles as membranes, electrodes, and hybrids in electrical‐driven membrane technologies. These systems leverage adsorption, catalysis, separation, and self‐cleaning but face challenges in stability, scalability ...
Zainab Alansari, Mariam Ouda, Shadi W. Hasan   +2 more
wiley   +1 more source

Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Background Darolutamide plus androgen‐deprivation therapy (ADT) improved metastasis‐free survival (MFS) by 2 years and reduced the risk of death by 31% in nonmetastatic castration‐resistant prostate cancer (nmCRPC) in ARAMIS. Prior local therapy may influence the efficacy of subsequent systemic therapy.
Matthias Saar, Karim Fizazi, Neal D. Shore, Matthew Smith, Jan‐Erik Damber, Andrey Semenov, Maria J. Ribal, Alison Birtle, Jérôme Rigaud, Christopher J. D. Wallis, Marc‐Oliver Grimm, Susan Halabi, Andrew J. Armstrong, Ateesha F. Mohamed, Patrick Adorjan, Shankar Srinivasan, Frank Verholen, Alicia K. Morgans, D. Robert Siemens   +18 more
wiley   +1 more source

Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor

, 2019
Marco Maccauro, Giulia Anna Follacchio, Carlo Spreafico, Jorgelina Coppa, Ettore Seregni   +4 more
openalex   +2 more sources

Combined ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option [PDF]

, 2020
Aadil Adnan, Sandip Basu
openalex   +1 more source

RADIONUCLIDIC TECHNIQUES

British Journal of Anaesthesia, 1974
openaire   +2 more sources

Molecular Deconvolution of Circulating “Other Cells”: A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving 177Lu‐DOTATATE PRRT

Cancer Medicine, Volume 15, Issue 1, January 2026.
ABSTRACT Purpose To assess the prognostic impact of pre‐treatment circulating other cells on treatment response and survival in neuroendocrine tumor (NET) patients receiving Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu‐DOTATATE. Methods Healthy donors (HDs, n = 81) and NET patients (n = 137) were analyzed.
Mahesh K. Padwal, Rahul V. Parghane, Sandip Basu, Bhakti Basu   +3 more
wiley   +1 more source

Geospatial assessment of natural radionuclides in urban soil of Chennai Metropolitan City. [PDF]

Sci Rep
Bharath KM, Bramha S, Chandrasekaran S, Krishnaveni M.   +3 more
europepmc   +1 more source